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ABSTRACT
ETS transcription factors mediate a wide array of
cellular functions and are attractive targets for
pharmacological control of gene regulation. We
report the inhibition of the ETS-family member
PU.1 with a panel of novel heterocyclic diamidines.
These diamidines are derivatives of furamidine
(DB75) in which the central furan has been
replaced with selenophene and/or one or both of
the bridging phenyl has been replaced with
benzimidazole. Like all ETS proteins, PU.1 binds
sequence specifically to 10-bp sites by inserting a
recognition helix into the major groove of a
50-GGAA-30 consensus, accompanied by contacts
with the flanking minor groove. We showed that
diamidines target the minor groove of AT-rich
sequences on one or both sides of the consensus
and disrupt PU.1 binding. Although all of the
diamidines bind to one or both of the expected
sequences within the binding site, considerable
heterogeneity exists in terms of stoichiometry,
site–site interactions and induced DNA conform-
ation. We also showed that these compounds accu-
mulate in live cell nuclei and inhibit PU.1-dependent
gene transactivation. This study demonstrates that
heterocyclic diamidines are capable of inhibiting
PU.1 by targeting the flanking sequences and
supports future efforts to develop agents for inhibit-
ing specific members of the ETS family.
INTRODUCTION
Transcription factors (TFs) are central to many cellular
process and account for 5–10% of genes in eukaryotes
(1). The central role of transcriptional regulation in
numerous cellular pathways provides strong rationale for
TFs as attractive targets for pharmacologic control (2–4).
Speciﬁcally, small-molecule inhibitors that block TFs from
binding to regulatory sites can lead to novel therapeutics
for a wide range of human diseases. They also complement
macromolecular approaches for inhibiting gene expression,
such as anti-sense oligonucleotides, RNAi and stapled
peptides, which suffer from weak metabolic stability and
poor cell uptake properties in vivo (5,6). Although the
design of small molecules that speciﬁcally modulate TFs
has proved challenging, recent activities have witnessed
signiﬁcant progress. For example, sequence-speciﬁc
polyamides have been shown to effectively block some
TFs from binding to their target DNA sites (7–11).
Heterocyclic diamidines have also shown excellent inhib-
ition of several TF-DNA complexes, with the potential for
development as anticancer therapeutics (12,13).
The ETS family of TFs controls a wide array of physio-
logic processes in many tissues (14–17) and is involved in a
large number of diseases, particularly cancers, in which it
causes aberrant gene expression (18–21). In addition, the
signaling pathways of several autoimmune diseases
depend on receptors (e.g. IL-2Rg, IL-7Ra, Toll-like recep-
tors), whose expression is regulated by speciﬁc ETS
members such as PU.1 (22–26). As sequence-speciﬁc
binding is an obligate step in ETS-mediated gene activa-
tion, inhibiting the appropriate ETS–DNA complex with
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small molecules offers signiﬁcant potential to impact
therapy for a broad range of diseases. All ETS proteins
share a conserved DNA binding domain that recognizes
sites harboring a 50-GGAA/T-30 consensus. The protein
inserts a-helix contacts into the major groove of the core
sequence, whereas loops interact with ﬂanking bases via
backbone contacts at the minor groove (14). These
ﬂanking sequences are often conserved for speciﬁc ETS
members, and compounds with high afﬁnity for binding
in the DNA minor groove may be developed as effective
allosteric inhibitors of ETS–DNA complexes.
In the present study, we report themodulation of PU.1 by
small molecules in vitro and in live cells. Recent thermo-
dynamic studies have advanced our molecular understand-
ing of sequence recognition by PU.1 (27–29). PU.1 belongs
toa restricted class ofETSproteins (class III) that is strongly
selective for AT-rich ﬂanking sequences, a feature that is
distinct from other ETS classes (30). We are interested in
the potential of AT-targeting heterocyclic diamidines to
inhibit the PU.1-DNA complex. As PU.1 and compound
are not directly competing for the same DNA binding site,
inhibition of major groove-binding TFs by minor-groove
binding small molecules is a complex task (9,31).
Here we demonstrate, using the B motif of the Ig2–4
enhancer (32), a high-afﬁnity PU.1 binding site with AT-
rich tracks ﬂanking both sides of the ETS consensus,
how gene-speciﬁc compound inhibition can be achieved
by targeting sequences that ﬂank the conserved GGAA
site. We have recently optimized a biosensor-surface
plasmon resonance (SPR)-based screen to identify com-
pounds that target the PU.1-B complex (27). Together
with additional characterization by electrophoretic
mobility shift and DNA footprinting, the data reveal
that, although all compounds examined bind to the
same expected motif(s) within the B site, signiﬁcant het-
erogeneity exists in terms of stoichiometry, site–site inter-
actions and induced DNA conformation. The compounds
also exhibit structure- and group-dependent differences in
PU.1 inhibition and nuclear localization in live unﬁxed
cells without detectable toxicity. These results establish
the potential of heterocyclic diamidines as viable thera-
peutics for PU.1 and other ETS family of TFs.
MATERIALS AND METHODS
DNA, protein and compounds
Synthetic DNA was obtained from Integrated DNA
Technologies (Coralville, IA, USA). The ETS domain of
murine PU.1 (residues 167–272) was overexpressed in
Escherichia coli and puriﬁed as described (28). The com-
pounds of Figure 1A were synthesized as previously
described and new compound synthesis is presented in
the Supplementary Methods. Their purity was veriﬁed
by NMR and elemental analysis. Concentrated stock
solutions (1mM) were prepared in water.
Biosensor-SPR assays for binding afﬁnity and PU.1-DNA
complex inhibition
SPR measurements were performed with a four-channel
Biacore T200 optical biosensor system (GE Healthcare).
A 50-biotin labeled hairpin DNA sample (Figure 1B) was
immobilized onto CM4 chips as previously described (27).
Detailed description of direct binding SPR experiment and
data analysis may be found in the SupplementaryMethods.
For compound inhibition studies, protein was injected
at a constant concentration of 100 nM onto the surface to
saturate DNA binding sites. Graded concentrations of
compound were then added to the protein solution. The
change in protein signal was plotted against compound
concentration with the midpoint of the transition taken
as IC50 (concentration required to achieve 50% protein
inhibition) value. Detailed descriptions of complementary
electrophoretic gel mobility shift assays are provided in
the Supplementary Methods.
DNA footprinting
Using the recombinant pUC19 plasmid described earlier
in text, internal primers were used to generate 100-bp
singly 50-radiolabeled B fragments by PCR. After puriﬁ-
cation by agarose gel extraction, the B fragment was
mixed with a saturating concentration of compound in
the same buffer as in gel mobility shift experiments. At
equilibrium, samples were digested with DNase I or chem-
ically generated hydroxyl radicals (OH) and subsequently
puriﬁed as previously described (28), along with selected
chemical sequencing reactions for base identiﬁcation.
After denaturing electrophoresis, the gel was dried and
digitized by phosphorimagery at a resolution of 200 mm.
Reporter assay for PU.1 activity in live cells
An expression plasmid encoding full-length PU.1 was
cloned between the NheI/BamHI sites of pcDNA3.1 (+).
Separately, the CMV promoter of a commercial enhanced
green ﬂuorescent protein (EGFP) reporter plasmid
(pEGFPLuc; Clontech) was replaced with a synthetic
enhancer element consisting of ﬁve tandem repeats of the
B site, spaced one helical-turn apart and followed by a
minimal TATA-box promoter (33). The PU.1 expression
and EGFP reporter plasmids are designated pcDNA-FL-
PU.1 and pB 5-EGFP, respectively. HEK293 cells,
cultured in RPMI 1680 medium containing 10% fetal
bovine serum under 5% CO2 at 37
C, were seeded in 24-
well plates (20 104 cells) and transfected with 500 ng of
pcDNA-FL-PU.1 after 24 h (JetPRIME, Polyplus-trans-
fection, Illkirch, France). The cells were retransfected
24 h later with 500 ng of the pB 5-EGFP plasmid with
or without compounds. Cellular ﬂuorescence was
quantiﬁed by ﬂow cytometry (excitation/emission=488/
510 nm). Counts were collected to >20 000 per sample,
corresponding to a CV of <5% for a 2% event frequency
and gated against untransfected controls to eliminate back-
ground. Separately, cell viability was evaluated by the
metabolic reduction of resazurin to ﬂuorescent resoruﬁn
(530/590 nm) using a commercial reagent (Cell-Titer Blue,
Promega) after incubation with the compounds for 24 h.
Fluorescence microscopy of cellular uptake of the
heterocyclic dications
HEK293 cells were seeded on chambered glass slides
(Lab-Tek; Corning), previously coated with poly-L-lysine,
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with 10 mM compounds for 24 h. Before microscopic
examination, doxorubicin (DOX) was added at 2 mg/ml
and incubated for 30min. Medium was removed and cells
were washed twice with PBS. The compounds and DOX
were visualized on a Zeiss Axio Observer.Z1 ﬂuorescence
microscope with a 365/445 nm and 570/630 nm ﬁlter set
(Chroma), respectively. Imagery was acquired with a
Hamamatsu ORCA-AG CCD camera. Colocalization
statistics were performed using Axiovision software
(Release 4.8.0.0; Zeiss) as described (34,35).
RESULTS
Heterocyclic diamidines target the minor groove of the jB
site, a high-afﬁnity cognate sequence for PU.1
Starting with DB75 (furamidine), a well-characterized
paradigm from the heterocyclic diamidine family, we
selected a panel of seven related compounds with a
variety of structures and functional groups (Figure 1A)
to determine whether they can inhibit binding of PU.1
to the B site. The compounds were ﬁrst screened for
binding to the B site by SPR analysis (Figure 2A and
Table 1). The parent DB75 bound the B site relatively
weakly (KD=0.53mM), and single modiﬁcations in terms
of substitution of the furan by selenophene (DB1213) or a
monobenzimidazole derivative (DB293) did not signiﬁ-
cantly improve afﬁnity. DB293 did exhibit a sigmoidal
binding curve, indicative of positively cooperative
binding as a stacked dimer to the 50-AAATAAA-30
sequence at the 50 side of the B site (Supplementary
Figure SD1), as previously observed with other sequences
for this compound (36). When the two modiﬁcations
in DB1213 and DB293 were combined (DB1281),
afﬁnity was improved by 10-fold. DB270 is the
bisbenzimidazole-furan analog of DB293 and it also
binds signiﬁcantly more tightly than DB293 and similarly
A
B
Figure 1. Heterocyclic diamidines and DNA target site used in this study. (A) Compounds are colored to aid visualization of the succeeding ﬁgures.
(B) The high-afﬁnity B site hairpin used in SPR experiments. The ETS consensus sequence (50-GGAA-30) is in bold.
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as the monobenzimidazole-selenophene DB1281.
Conversion of the furan in DB270 to a selenophene
(DB1976) again produced a signiﬁcant jump in binding
afﬁnity. B-bound selenophene dications show strong,
positive-induced circular dichroism spectra between
350–400 nm (Supplementary Figure SD2), indicative of
similar minor-groove recognition as previously established
for the furan analogs (37,38). In summary, these com-
pounds bind strongly in the DNA minor groove with
structure-dependent variations in binding afﬁnity.
Heterocyclic diamidines inhibit PU.1 binding at the
jB site
We have previously optimized SPR for characterizing
PU.1–DNA interactions and displacement of PU.1 by
the minor-groove binder distamycin (27). With B sites
immobilized in a DNA hairpin duplex a 100 nM solution
of the PU.1 ETS domain was injected over the surface
with increasing compound concentrations. The strong
protein SPR signal diminished as the protein–DNA
complex was titrated with increasing concentrations of
compounds (Supplementary Figure SD3). This is a clear
demonstration that minor-grove binding diamidines, such
as those in Figure 1A, are able to block the ability of the
PU.1 protein to bind site speciﬁcally in the DNA major
groove. Steady-state signals were used to determine IC50
values in Figure 2C and Table 1. A summary of IC50
versus KD is shown in Figure 2C.
DB75 does not inhibit PU.1 binding and its selenophene
analog, DB1213 is a relatively weak inhibitor,
IC501.5 mM. With increasing concentrations of the
closely related compound, DB293, which has a single
phenyl of DB75 replaced by a benzimidazole, the SPR
signal is reduced by the maximum amount by 1 mM con-
centration (Figure 2B). The residual signal is primarily a
result of DB293 binding in the minor groove of DNA and
non-speciﬁc protein binding (27). The protein inhibition
curve of DB293 also has a sigmoidal appearance showing
cooperative protein inhibition with a moderate IC50
(Table 1). The selenophene analog of DB293, DB1281,
binds more strongly (KD=30nM) to the DNA than
DB293 and DB1281 binding results in strong PU.1-
DNA inhibition (IC50=50 nM). The bisbenzimidazole
furan analog of DB293, DB270, binds better than
DB293 but, surprisingly, inhibits the PU.1-DNA
complex weakly. DB1976, the selenophene analog of
DB270, however, potently inhibits PU.1 binding
(IC50=10 nM), in good agreement with the high
DB1976-B afﬁnity (KD=12nM). DB1977 with an
imidazoline modiﬁcation at the amidines gives similar
binding constants and IC50 values to DB1976.
To test the SPR data, we used the electrophoretic
mobility shift assay (EMSA) to assess the inhibition of
PU.1 binding by DB293, DB1281, DB1976 and DB1977
(Supplementary Figure SD4 and Table 1). Overall, the
results are in agreement with the SPR measurements,
but they also reveal additional compound-speciﬁc
A B C
Figure 2. SPR analysis of the dications binding to the B site and inhibition of PU.1. (A) The binding of compounds to an immobilized DNA
hairpin duplex harboring the B site was determined by SPR. The r values (as explained in the Supplementary Methods) are plotted against
compound concentration. An appropriate one or two site (DB293) model was used to ﬁt the data. Additional points at higher concentration
were used to obtain the KD values for DB75 and DB1213. DB1977 is similar to DB1976 and is not shown. Numerical estimates of KD are given
in Table 1. (B) The protein inhibition signal in percentage is plotted against compound concentration. Numerical estimates of IC50 are given in
Table 1. (C) Comparison of DNA-binding afﬁnity and PU.1-inhibitory potency of DB compounds. For DB293, the KD value for binding the ﬁrst
equivalent of drug is used.
Table 1. Binding afﬁnities and PU.1-inhibitory potencies of hetero-
cyclic diamidines
Compound
Direct
binding
PU.1 inhibition
SPR SPR EMSA Live cells
log KD
a log IC50 log IC50
b nHb log IC50b
DB1977 8.00 8.60 8.51±0.11 1.5±0.30 6.24±0.03
DB1976 7.92 8.00 8.09±0.07 0.86±0.13 5.42±0.04
DB1281 7.53 7.30 7.79±0.05 1.4±0.2 >4
DB293 6.65, 6.46 6.47±0.03 2.3±0.3
7.42
DB270 7.74 —c
DB1213 6.32 5.8
DB75 6.27 —c
aFitted value from Equation (2) in Supplementary Methods.
bFitted values from Equation (3) in Supplementary Methods.
cInsufﬁcient inhibition to estimate IC50.
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features in PU.1 inhibition. Speciﬁcally, comparison of the
DB293/DB1281 pair shows that DB293 (the parent furan)
inhibits PU.1 with a Hill coefﬁcient (nH) of 2.3±0.3, in
agreement with the SPR data (Figure 2B). Interestingly,
the selenophene displaces PU.1 with greater apparent
potency but less cooperatively, albeit with a Hill coefﬁ-
cient still well over unity, highlighting the lack of any
coupling between positively cooperative binding and
high afﬁnity/inhibitory potency.
In the case of DB1976/DB1977 pair, which differs in
terms of their terminal dications, both compounds
inhibit PU.1 ETS binding with similarly low IC50 values
(Table 1), but the associated Hill coefﬁcient for DB1976
(0.86±0.13) is signiﬁcantly lower than DB1977
(1.5±0.3). The fractional Hill coefﬁcient for DB1976
suggests that it binds two or more sites in the B motif
or a single site with negative cooperativity (or a combin-
ation of both). In our empirical ﬁt of the data to total
compound concentration, depletion of high-afﬁnity
ligand would overestimate the Hill coefﬁcient (39). The
situation with DB1977 is additionally complicated by its
poor solubility and tendency to aggregate; it was not
possible to maintain DB1977 above 0.1 mM in Tris
buffer. We, therefore, expect the true values of nH for
DB1976 to be <0.86 still and for DB1977, closer to
unity. In summary, compound modiﬁcations profoundly
affect the ability of the dications to inhibit TFs, from no to
lownM inhibition.
Structural heterogeneity in compound-jB binding
To understand the compound-speciﬁc differences in PU.1
inhibition in greater detail, we performed DNA footprint-
ing to identify where the four compounds, examined by
electrophoretic mobility shift, bind in the B motif. Using
DNase I and hydroxyl radical (OH) as minor-groove
probes, we compared the footprints of a DNA fragment
harboring the B motif at saturating concentrations of
compounds relative to the unbound state. For the
DB293/DB1281 pair (Figure 3), DB1281 protected the
B motif from OH prominently at both minor grooves
(marked S1 and S2) ﬂanking the ETS core consensus
(50-GGAA-30). In contrast, even at a saturating concentra-
tion of 0.1mM, DB293 appeared to bind only the S1 site
(the AT-rich track 50 to the GGAA consensus), and pro-
tected against OH more weakly than DB1281. We inde-
pendently veriﬁed DB293 binding to S1 and the negligible
occupancy at S2 by DNase I footprinting (Supplementary
Figure SD1). Remarkably, occupancy at S1 by DB293
induces a distinct hypersensitivity to OH at positions
(asterisks in Figure 3) distal to its binding site at S1,
A B
Figure 3. DB293 induces distinct DNA conformations at the B motif that are not shared by its homolog DB1281. A DNA fragment harboring
the B site was saturated with DB293 (0.1mM) or DB1281 (1 mM) and probed by hydroxyl radicals (OH). Shown here are the lane traces for the
50-GGAA-30 and 50-TTCC-30 strands; the experimental gel images are found in Supplementary Figure SD5. The pixel count is marked in the abscissa.
Note the 30!50 direction from left to right. Although the two OH footprints within the B motif for DB1281 are apparent, neither strand exhibits
protection by DB293 at S2. Instead, DB293 induces local hypersensitivity to OH at both strands just 30 to the CC. DNase I footprinting conﬁrms
the weak footprint at S1 and negligible occupancy at S2 for DB293 (Supplementary Figure SD1).
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reaching as far as bases corresponding to S2. Taken
together with the SPR and gel shift data, we conclude
that DB293 binds as a cooperative dimer (nH 2), albeit
weakly, at a single ﬂanking site S1 (50-ATAAAA-30). The
lower apparent Hill coefﬁcient (nH 1.4) for DB1281 then
follows as a consequence of a second high-afﬁnity binding
site at S2.
In the case of DB1976 and DB1977, DNase I footprint-
ing detects a strong binding site in the AT-rich track (50-A
TAAAA-30) upstream from the ETS consensus
(S1) (Figure 4A and B). The OH footprinting identiﬁes
a second binding site (50-AAAC-30 in S2) in the other
ﬂanking segment for DB1976 only (Figure 4C and D).
These two sites are sufﬁciently separated to account
for the fractional Hill coefﬁcient associated with
DB1976. Evidence that the two sites interact may
be found in the DNase I footprints, in which bases
between S1 and S2 (hollow square and hollow circle
in Figure 4A and B) are also protected by DB1976 but
not DB1977. In summary, the underlying effects
of compound binding and induced changes in DNA struc-
ture are signiﬁcant and variable from one compound to
the next.
The heterocyclic dications inhibit PU.1-dependent
transactivation differentially in live cells
To probe the potential of compounds to inhibit gene ac-
tivation by PU.1 in vivo, we developed a speciﬁc cell-based
reporter assay for PU.1. We cloned a reporter plasmid,
pB5-EGFP, in which a series of 5 tandem B
motifs were placed just upstream from a minimal
TATA-promoter to drive the expression of an EGFP
reporter. Speciﬁcity for PU.1 is conferred by using a cell
line, HEK293, which does not natively express PU.1.
Thus, transfection of pB5-EGFP in HEK293 generated
no signal beyond the autoﬂuorescence of untransfected
cells (Figure 5A). Prior transfection with an expression
plasmid for PU.1 24 h before transfecting pB5-EGFP
readily activated the reporter. Without binding sites
for additional TFs, the transactivation efﬁciency of
pB5-EGFP is relatively low (10%). To ensure
reliable counting statistics by ﬂow cytometry, we have
gated and statistically powered our measurements
(>20 000 counts/sample) to detect a 2% event frequency
with a CV of <5%.
We tested the inhibition of EGFP ﬂuorescence from
pB5-EGFP by titrating the three compounds in our
series that demonstrate the lowest IC50: DB1976,
DB1977 and DB1281. Although DB1976 and DB1977
inhibit cellular EGFP ﬂuorescence with an IC50 3 mM
and 0.5 mM (Table 1), respectively, DB1281 exerts no
apparent effect up to an extracellular concentration of
100mM (Figure 5B). To probe whether the loss of
cellular EGFP ﬂuorescence may be due to compound-
induced cytotoxicity, we assayed the metabolic status of
HEK293 cells by resazurin reduction at the same
compound concentrations. None of the three compounds
were toxic to HEK293 cells at concentrations up to 10 mM,
demonstrating the inhibition of EGFP signal was not
due to indirect effects related to cytotoxicity (Figure 5B).
In summary, DB1976 and DB1977 inhibit PU.1-speciﬁc
gene transactivation in live cells, and do so without
toxicity.
Localization of compounds in live unﬁxed cells
To further understand the biological basis of these unex-
pected differences in PU.1 inhibition among the com-
pounds, we evaluated the cellular uptake of the
compounds by ﬂuorescence microscopy. The compounds
absorb between 350–400 nm (c.f. Supplementary
Figure SD2) and emit a blue ﬂuorescence. HEK293 cells
were incubated with 10 mM compounds for 24 h and then
counterstained with 2 mg/ml DOX for 30min. DOX ﬂuor-
esces at a non-overlapping wavelength (red) and rapidly
concentrates in live (unﬁxed) cell nuclei without short-
term toxicity (40,41). Nuclear uptake of the heterocyclic
cations was visualized and measured in terms of
colocalization with DOX. All three compounds codistrib-
ute extensively with DOX, indicative of nuclear selectivity
(Figure 6A). Quantitative analysis, however, reveal differ-
ences among the three compounds (Figure 6B). On one
hand, the ﬂuorescence of DB1976 not only quantitatively
co-occurs with DOX but also correlates strongly in signal
intensity (r=0.90). On the other hand, a signiﬁcant
fraction of DB1281 ﬂuorescence (16%) did not colocalize
with DOX, and the colocalized ﬂuorescence intensities of
DB1281 and DOX are less correlated (r=0.58; arrows in
Figure 6A). DB1977 exhibits intermediate colocalization
and correlation with DOX. In summary, DB1976 is
largely localized similarly to DOX in the nucleus,
whereas DB1281 and, to a lesser extent, DB1977, associate
with cellular components outside the nucleus, and hetero-
geneously within the nucleus.
DISCUSSION
Our expanding knowledge of genes, their regulatory
sequences, as well as the TFs and enzymes which
regulate their expression provides attractive targets for
external control by designed small molecules. Design of
small molecules to target TFs, however, has not been
highly successful. The TFs lack the substrate and inhibitor
binding sites normally present in enzymes and this makes
small molecule design to speciﬁcally target them difﬁcult.
A natural approach is to target TFs is to modulate their
binding to DNA. The development of DNA-binding poly-
amides has produced some promising results (7–11). Aryl
diamidines and related compounds have a long history
of use as pharmaceuticals and as nuclear stains in cells.
For these reasons we are pursuing these compounds as
potential TF inhibitors. We report here a new series of
heterocyclic diamidines or di-imidazolines that include
potent inhibitors of the ETS TF PU.1 at the protein–
DNA level. All ETS proteins recognize 10-bp sites harbor-
ing a central 50-GGAA/T-30 core consensus and variable
ﬂanking sequences. The ﬂanking sequences are non-
random and genomic studies have established clear
sequence preferences for high-afﬁnity binding by subsets
of ETS members in vivo (42). PU.1 belongs to a small class
of ETS proteins (class III) that are strongly selective for
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AT-rich ﬂanking sequences, a feature distinct from other
ETS classes (30,43). Together with potential applications
of PU.1 inhibition in several autoimmune disorders, our
data represent a signiﬁcant advance in transcriptional
control of ETS TFs.
Structure-function relationships in jB-binding and PU.1
inhibition by compounds
As the compounds bind in the DNA minor groove, they
must inhibit PU.1 binding by an allosteric mechanism.
A B
C D
Figure 4. The homologs DB1976 and DB1977 differentially recognize AT-rich sequences within the B motif, a PU.1-speciﬁc binding site. A DNA
fragment harboring the B site was saturated with DB1976 (1mM) or DB1977 (0.1 mM) and probed by DNase I (A and B) or hydroxyl radicals
(OH; C and D). Shown here are the lane traces for the 50-GGAA-30 and 50-TTCC-30 strands; the experimental gel images are found in
Supplementary Figure SD6. The pixel count is marked in the abscissa. Note the 30 ! 50 direction from left to right. Bases marked by hollow
symbols (square, circle) are signiﬁcantly more protected against DNase I by DB1976 than DB1977. DNase I protection by DB1976 may, therefore,
be considered as a single, extended footprint. Whereas the two OH footprints for DB1976 are apparent (S1 ad S2), neither strand exhibits protection
by DB1977 at S2.
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AB
Figure 5. Inhibition of PU.1-speciﬁc gene transactivation in live cells. (A) PU.1 activity was assayed using an EGFP reporter under the control of a
minimal TATA-box promoter. An enhancer element consisting of ﬁve tandem B sites, spaced one helical turn apart, confers speciﬁcity to PU.1.
Reporter expression was measured by ﬂow cytometry. The HEK293 cells, which do not express PU.1, do not activate the reporter except in the
presence of exogenous PU.1 (as shown in ﬂuorescence micrograph). (B) PU.1-expressing HEK293 cells were transfected with reporter plasmid with or
without DB1976, DB1977 or DB1281 in the culture medium at the indicated concentrations. EGFP ﬂuorescence was measured by ﬂow cytometry
after 24 h. The effect of the compounds on cell viability was separately determined by resazurin reduction.
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Figure 6. Localization of DB compounds in live unﬁxed HEK293 cells. (A) The uptake of DB1281, DB1976, and DB1977 by HEK293 cells and
colocalization with DOX were monitored by ﬂuorescence microscopy as described in ‘Materials and Methods’. Arrows indicate cells that show
particularly strong DOX staining in DB1281. (B) Quantitative colocalization analysis of the dications and DOX ﬂuorescence in terms of spatial
co-distribution and intensity correlation. DB1281 correlates comparably as DB1976 and DB1977 in terms of spatial codistribution with DOX but not
DOX intensity.
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Our goal in this work was to ﬁnd compounds that are
most effective at this type of inhibition. Single modiﬁca-
tions of furamidine, DB75, resulted in minor gains in
afﬁnity for the B site. Such was the case whether the
modiﬁcation was a furan ! selenophene (DB1213) or
phenyl ! monobenzimidazole (DB293) substitution.
However, the combined modiﬁcations in DB1281
improved afﬁnity by 10 fold. These observations are
reminiscent of the related thiophene derivative, DB818,
which binds better than DB293 to the minor groove in
AT sequences due to a better optimized shape for
minor-groove recognition (44). In the case of DB1281,
however, the footprinting data implicate a second high-
afﬁnity site downstream from the 50-GGAA-30 ETS con-
sensus as an additional reason for the enhanced afﬁnity.
In a similar way, replacement of the second phenyl by
benzimidazole in DB270 improved afﬁnity similarly as
DB1281. The extra surface area of the additional
benzimidazole for interaction with the walls of the minor
groove and the extra H-bonding benzimidazole-NH are
responsible for this improvement. Surprisingly, DB270 is
a poor competitor for PU.1 binding, and additional
studies are underway to determine the cause of its lack
of inhibition. Importantly DB1976, the selenophene
analog of DB270, potently inhibits PU.1. Thus, the inhib-
ition disadvantage in DB270 is effectively relieved by the
larger C-Se-C bond angle in DB1976 (38). It seems likely
that the Se derivative is a much better allosteric effector
for PU.1 inhibition.
Heterogeneity in compound-jB interactions
The SPR and gel mobility shift titrations as well as DNA
footprinting data reveal structural and conformational
heterogeneity that attends the sequence-selective binding
of the dications. We observed heterogeneity in terms of the
number of binding sites along the B motif and conform-
ation of the compounds bound to DNA. In addition to
the AT-rich binding site (S1) just upstream from the 50-
GGAA-30 ETS consensus, DB1281 and DB1976 also bind
at a second AT-rich site (S2) downstream from the con-
sensus. In the case of DB1281, its greater potency in PU.1
inhibition relative to DB293 may, at least in part, be
attributed to the availability of S2 as occupancy by the
drug at either site would displace the protein. However,
the presence of a second binding site for DB1976 has a
much more marginal effect on PU.1 inhibition and direct
binding afﬁnity. These comparisons indicate that neither
the location nor number of binding sites alone dictates the
overall behavior of a compound in terms of binding
afﬁnity or inhibitory potency and imply complex site–
site interactions for compounds such as DB1976.
As direct interactions between compounds in the DNA-
bound state may be discounted, the notion of site–site
interactions requires conformational changes in the
intervening DNA to communicate the occupancy at each
site. The footprinting data show that induced DNA con-
formation occurs and represents another important deter-
minant of the thermodynamics of compound binding.
Allosteric effects of the bound molecules on the protein–
DNA interactions at both ﬂanking sequences of the
GGAA consensus could, therefore, synergistically
modulate PU.1 binding more than either alone. The
binding of DB293 to a speciﬁc ﬂanking site (S1)
upstream from the ETS consensus, for example, induces
conformation changes in the 30 direction that are detect-
able as minor-groove hypersensitivity to hydroxyl radicals
(OH). Similarly, the occupancy of DB1976 at sites
ﬂanking both sides of the ETS consensus induces con-
formational changes in the intervening sequence, but in
the case detectable as minor-groove protection against
DNase I. Therefore, these conformational changes are
speciﬁc to each compound, indicating the ability of even
short sequences to discriminate among them. In particu-
lar, the speciﬁcity of compound-induced conformational
changes further implies that, although they all bind to the
S1 site, the details of their interactions with DNA contacts
in the minor groove are likely different. Our data highlight
the utility of DNase I and OH footprinting as comple-
mentary probes that are sensitive to local structural
microheterogeneity. In summary, locally compound-
induced DNA structural changes, even of different
types, are successful in producing effective allosteric
inhibitors of PU.1. The structure and compound
property space for the compounds in Figure 1A
produces a surprising range of effects on DNA and espe-
cially, on inhibition of PU.1 binding.
Inhibition of PU.1 in live cells
To demonstrate the feasibility of inhibiting PU.1 with het-
erocyclic diamidines in vivo, we used a reporter-based
assay designed to respond to transactivation by PU.1.
The data show that DB1976 and DB1977 inhibited PU.1
activity with IC50 in the sub- to low-micromolar range.
These values, which are 102-fold higher than those
observed in SPR or gel shift experiments (Table 1), are
expected owing to the protected nature of DNA in the
nucleus. Signiﬁcantly, DB1281, which strongly inhibits
speciﬁc PU.1 binding in vitro, shows no detectable
activity in live cells. As none of the compounds tested
exhibit detectable cytotoxicity (Figure 5B), more subtle
biological factors are at play. Although all three com-
pounds codistribute extensively in the nucleus, signiﬁcant
quantitative differences exist among them (Figure 6).
DB1281, in particular, exhibits signiﬁcant distribution
outside the nucleus (not colocalized with DOX) as well
as a peculiar distribution within the nucleus (low correl-
ation with colocalized DOX). Thus, a substantial fraction
of intracellular and even intranuclear DB1281 may be
sequestered, and therefore unavailable for binding to its
target sites. This is a critical feature of compound biolo-
gical activity that is often overlooked. We note that our
use of DOX as a nuclear counterstain was aimed at
preserving the biological disposition of the test com-
pounds by avoiding potential artifacts of ﬁxation
(required, for example, with the use of propidium) on
DNA binding ligands (45). The lack of toxicity and per-
turbation on cellular function due to short-term (30min.)
exposure to DOX is also well-established (40,41). Thus, we
consider our results to be biologically reliable.
For applications outside of cancer chemotherapy or im-
munosuppression, correction of aberrant gene expression
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without adversely affecting cell viability is highly desir-
able. The ability of DB1976 and DB1977 to abolish
PU.1-dependent gene transactivation without detectable
toxicity is, therefore, a signiﬁcant feature. This is in
contrast to the reported cytotoxicity of some dications at
106 M concentrations in cultured cancer cell lines (46).
This difference may possibly be related to our use of a
non-malignant cell line (HEK293). Given the potential
of PU.1 inhibition in non-cancer indications, the lack of
apparent cytotoxicity is a welcome and encouraging result
of our study. The low toxicity also suggests that these type
compounds can be developed for humans, and the exten-
sive clinical experience with diamidines in the treatment of
trypanosomiasis and other diseases (47) is a signiﬁcant
advantage over other classes of DNA-targeting agents.
In conclusion, the effective cellular inhibition of the
PU.1 TF observed here with a new series of heterocyclic
dications shows that this class of compounds has promise
for development as therapeutics for speciﬁc inhibition of
TF–DNA complexes. The variety of effects and exciting
inhibition results produced by the set of compounds in our
study highlights the need to conduct a wider range of
experiments in our efforts to understand, design and
develop DNA-targeted TF inhibitors.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online,
including [37,38,48,49].
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